查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1476336

到 2030 年異位性皮膚炎治療藥物的市場預測：按藥物類別、嚴重程度、劑型、給藥途徑、用途和地區進行全球分析

Atopic Dermatitis Drugs Market Forecasts to 2030 - Global Analysis By Drug Class, Severity, Formulation, Route of Administration, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球異位性皮膚炎藥物市場規模為 136.2 億美元，預計 2030 年將達到 254.8 億美元，預測期內複合年成長率為 8.1%。

異位性皮膚炎藥物是指用於治療異位性皮膚炎症狀的藥物，異位性皮膚炎是一種以搔癢、發紅和皮疹為特徵的慢性發炎皮膚病。透過解決潛在的免疫系統功能障礙，異位性皮膚炎治療可以減緩疾病進展並最大限度地減少長期併發症。異位性皮膚炎治療可以減緩疾病進展並增強皮膚的屏障功能，使患者能夠更好地管理自己的病情並改善整體健康和生產力。

根據世界衛生組織（WHO）統計，2017年有超過9億人患有皮膚病，其中五種常見皮膚病約佔皮膚病的80%。異位性皮膚炎是一種常見的慢性發炎皮膚病，影響全球 15% 至 20% 的兒童和 1% 至 3% 的成人。

異位性皮膚炎增加

隨著越來越多的患者尋求治療，對有效藥物治療的需求也增加。需求的激增刺激了研究和開發工作，並導致了創新治療方法的推出。此外，不斷擴大的患者群體為製藥公司創造了更大的市場機會，鼓勵對藥物開發和行銷策略的投資。因此，異位性皮膚炎盛行率的上升直接推動了異位性皮膚炎治療藥物市場的成長。

副作用和安全問題

異位性皮膚炎藥物的副作用和安全性問題包括免疫抑制、感染疾病風險增加、皮膚刺激和過敏反應。這些副作用限制了某些藥物的使用並影響患者的用藥順從性和治療結果。此外，安全問題會增加監管審查、延長核准流程並增加開發成本。頻繁的副作用也會導致患者不滿意，降低對現有治療方法的信心，並阻礙市場成長。

醫療保健支出增加

醫療保健支出的增加增加了患者獲得治療選擇的機會。分配給醫療保健的更多財政資源將使人們能夠負擔昂貴的生物製藥和異位性皮膚炎的新療法。此外，醫療保健支出的增加通常與基礎設施、醫療保健服務和病患教育的改善有關，從而導致更早診斷和開始治療。總體而言，醫療保健支出的成長趨勢正在創造有利於異位性皮膚炎治療藥物的市場擴張和創新的環境。

非專利衝突

當原廠藥的專利到期並且學名藥製造商能夠以更低的價格生產和銷售同等產品時，就會出現特應性皮膚炎治療學名藥的競爭。結果，製藥公司的盈利較低，投資於創新治療方法研發的獎勵也較少。此外，學名藥競爭限制了患者獲得新的和可能更有效的治療方法，影響了整體市場需求和成長。

COVID-19 的影響

COVID-19 的爆發對異位性皮膚炎治療藥物市場產生了重大影響。醫療服務的關閉和中斷導致異位性皮膚炎患者的診斷和治療開始延遲。此外，經濟不確定性減輕了患者的經濟負擔，並減少了獲得昂貴生物製藥的機會。新療法的臨床試驗也面臨延誤，影響了管線進展。整體而言，市場挑戰與機會並存，對成長和創新有長期影響。

錠劑市場預計將在預測期內成為最大的市場

錠劑市場預計將出現良好的成長。異位性皮膚炎是一種慢性發炎皮膚病，通常透過口服錠劑藥物進行治療。這些藥物旨在緩解搔癢、發炎和皮疹等症狀。當異位性皮膚炎廣泛或嚴重時，它尤其有效。這些錠劑是治療異位性皮膚炎的綜合方法的一部分，通常與局部治療和生活方式改變相結合。

預計發炎領域在預測期內複合年成長率最高

預計發炎領域在預測期內將出現最高的複合年成長率。異位性皮膚炎是一種慢性發炎皮膚病，有多種針對發炎的藥物干預措施。調節免疫反應和減少發炎可以預防疾病發作並促進長期緩解。整體而言，發炎作用不僅可以緩解不適，還可以降低與慢性異位性皮膚炎相關的併發症的風險。

比最大的地區

由於盛行率上升、醫療保健支出增加以及對異位性皮膚炎的認知不斷增強，預計亞太地區將在預測期內佔據最大的市場佔有率。日本、中國和韓國等國家由於患者人數眾多且醫療保健機會的改善，為市場擴張做出了重大貢獻。此外，製藥公司和當地醫療保健提供者之間的合作正在推動市場滲透。總體而言，在不斷發展的醫療基礎設施和不斷提高的患者意識的推動下，亞太地區的異位性皮膚炎治療市場預計將持續擴張。

複合年成長率最高的地區：

由於異位性皮膚炎的高發病率、先進的醫療基礎設施以及研發方面的高投資，預計北美在預測期內將呈現最高的複合年成長率。美國主導市場，大部分收益來自生物製藥和局部皮質類固醇。此外，該地區完善的製藥業和強大的法律規範支持創新治療方法的開發和商業化。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球異位性皮膚炎治療藥物市場：依藥物類別

  • 皮質類固醇
  • Calcineurin抑制劑
  • 全身性免疫抑制劑
  • 磷酸二酯酶 4 (PDE4) 抑制劑
  • 抗組織胺藥
  • 其他藥物類別

第6章全球異位性皮膚炎治療藥物市場：依嚴重程度分類

  • 輕微症狀
  • 中度疾病
  • 病情嚴重

第7章全球異位性皮膚炎治療藥物市場：按劑型

  • 錠劑
  • 洗劑
  • 糖漿
  • 噴劑
  • 其他劑型

第8章全球異位性皮膚炎治療藥物市場：途徑

  • 外用藥
  • 口腔醫學
  • 注射藥物

第9章全球異位性皮膚炎治療藥物市場：依應用分類

  • 照光治療
  • 免疫調節
  • 預防感染
  • 皮膚屏障功能障礙
  • 發炎
  • 癢
  • 其他用途

第10章全球異位性皮膚炎治療藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Sanofi
  • Regeneron Pharmaceuticals
  • Pfizer Inc.
  • Novartis AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • LEO Pharma A/S
  • Galderma SA
  • Johnson & Johnson
  • Bristol Myers Squibb
  • AnaptysBio Inc.
  • Encore Dermatology Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Glenmark Pharmaceuticals
Product Code: SMRC25882

According to Stratistics MRC, the Global Atopic Dermatitis Drugs Market is accounted for $13.62 billion in 2023 and is expected to reach $25.48 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Atopic Dermatitis Drugs refer to pharmaceuticals used to manage the symptoms of atopic dermatitis, a chronic inflammatory skin condition characterized by itching, redness, and rash. By addressing the underlying immune system dysfunction, these drugs help in controlling the disease progression and minimizing long-term complications. By controlling the disease progression and enhancing skin barrier function, atopic dermatitis drugs empower patients to better manage their condition, leading to improved overall well-being and productivity.

According to the World Health Organization (WHO), over 900 million people were affected with skin disease in 2017, and around 80% of the skin disorders are accounted for by the five common skin disorders. Atopic dermatitis, a common and chronic inflammatory skin disease, affects 15% to 20% of children and 1% to 3% of adults across the world.

Market Dynamics:

Driver:

Rising incidence of atopic dermatitis

With an increasing number of patients seeking treatment, there is a growing demand for effective pharmaceutical interventions. This surge in demand stimulates research and development efforts, leading to the introduction of innovative therapies. Moreover, the expanding patient pool creates a larger market opportunity for pharmaceutical companies, encouraging investment in drug development and marketing strategies. Consequently, the rising prevalence of atopic dermatitis directly fuels the growth of the atopic dermatitis drugs market.

Restraint:

Side effects and safety concerns

Side effects and safety concerns in atopic dermatitis drugs include immunosuppression, increased risk of infections, skin irritation, and allergic reactions. These adverse effects limit the widespread use of certain medications, impacting patient adherence and treatment outcomes. Moreover, safety issues raise regulatory scrutiny, prolonging approval processes and increasing development costs. High incidences of side effects also lead to patient dissatisfaction, reducing confidence in available treatments and hindering market growth.

Opportunity:

Rising healthcare expenditure

Rising healthcare expenditure enhances patient access to treatment options. With greater financial resources allocated to healthcare, individuals can afford expensive biologic drugs and novel therapies for atopic dermatitis. Moreover, increased healthcare spending often correlates with improved infrastructure, healthcare services, and patient education, leading to earlier diagnosis and treatment initiation. Overall, the uptrend in healthcare expenditure creates a conducive environment for market expansion and innovation in atopic dermatitis therapeutics.

Threat:

Generic competition

Generic competition in atopic dermatitis drugs arises when patents for branded medications expire, allowing generic drug manufacturers to produce and sell equivalent versions at lower prices. As a result, pharmaceutical companies face decreased profitability and reduced incentives for investing in research and development of innovative treatments. Additionally, generic competition limits patient access to newer, potentially more effective therapies, impacting overall market demand and growth.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the atopic dermatitis drugs market. Lockdowns and disruptions in healthcare services have led to delays in diagnosis and treatment initiation for atopic dermatitis patients. Additionally, economic uncertainties have reduced patient affordability and access to expensive biologic drugs. Clinical trials for new treatments have also faced delays, affecting pipeline progress. Overall, the market has experienced a mix of challenges and opportunities, with long-term implications for growth and innovation.

The tablets segment is expected to be the largest during the forecast period

The tablets segment is estimated to have a lucrative growth. Atopic dermatitis, a chronic inflammatory skin condition, is often managed through oral medications in tablet form. These drugs aim to alleviate symptoms such as itching, inflammation, and rash associated with the condition. They offer systemic relief, targeting inflammation from within, which can be particularly effective for widespread or severe cases of atopic dermatitis. These tablets are part of a comprehensive approach to managing atopic dermatitis, often combined with topical treatments and lifestyle modifications.

The inflammation segment is expected to have the highest CAGR during the forecast period

The inflammation segment is anticipated to witness the highest CAGR growth during the forecast period. Atopic dermatitis, a chronic inflammatory skin condition, sees several drug interventions targeting inflammation. By modulating immune responses and reducing inflammation, they can prevent disease flare-ups and promote long-term remission. Overall, their efficacy in controlling inflammation not only relieves discomfort but also mitigates the risk of complications associated with chronic atopic dermatitis.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period due to rising prevalence, increasing healthcare expenditure, and expanding awareness about the condition. Countries like Japan, China, and South Korea are key contributors to market expansion due to their large patient populations and improving access to healthcare. Additionally, partnerships between pharmaceutical companies and local healthcare providers facilitate market penetration. Overall, the Asia-Pacific Atopic Dermatitis Drugs Market is poised for continued expansion fuelled by evolving healthcare infrastructure and growing patient awareness.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to high prevalence of atopic dermatitis, sophisticated healthcare infrastructure, and significant investments in research and development. The United States dominates the market, with a significant portion of revenue attributed to biologic drugs and topical corticosteroids. Further, the region's well-established pharmaceutical industry and strong regulatory framework support the development and commercialization of innovative therapies.

Key players in the market

Some of the key players profiled in the Atopic Dermatitis Drugs Market include Sanofi, Regeneron Pharmaceuticals, Pfizer Inc., Novartis AG, Eli Lilly and Company, AbbVie Inc., Astellas Pharma Inc., LEO Pharma A/S, Galderma S.A., Johnson & Johnson, Bristol Myers Squibb, AnaptysBio Inc., Encore Dermatology Inc., GlaxoSmithKline PLC, AstraZeneca PLC and Glenmark Pharmaceuticals.

Key Developments:

In January 2024, Pfizer and Glenmark Pharmaceuticals announced that they had collaborated to launch abrocitinib, an oral treatment for moderate-to-severe atopic dermatitis (AD) in India. Pfizer developed abrocitinib, which has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO). Glenmark and Pfizer will co-market the product under the brand names Jabryus and Cibinqo, respectively.

In January 2024, Sanofi's Dupixent (dupilumab) has been approved for use in treating moderate to severe atopic dermatitis in patients aged 12 and older in the European Union. It is also the first and only biologic medicine in India that has shown improved disease signs, symptoms, and quality of life measures for atopic dermatitis.

Drug Classes Covered:

  • Corticosteroids
  • Calcineurin Inhibitors
  • Systemic Immunosuppressants
  • Phosphodiesterase-4 (PDE4) Inhibitors
  • Antihistamines
  • Other Drug Classes

Severities Covered:

  • Mild
  • Moderate
  • Severe

Formulations Covered:

  • Tablets
  • Lotions
  • Syrups
  • Sprays
  • Other Formulations

Route of Administrations Covered:

  • Topical Drugs
  • Oral Drugs
  • Injectable Drugs

Applications Covered:

  • Phototherapy
  • Immunomodulation
  • Infection Prevention
  • Skin Barrier Dysfunction
  • Inflammation
  • Itching
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Atopic Dermatitis Drugs Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Corticosteroids
  • 5.3 Calcineurin Inhibitors
  • 5.4 Systemic Immunosuppressants
  • 5.5 Phosphodiesterase-4 (PDE4) Inhibitors
  • 5.6 Antihistamines
  • 5.7 Other Drug Classes

6 Global Atopic Dermatitis Drugs Market, By Severity

  • 6.1 Introduction
  • 6.2 Mild
  • 6.3 Moderate
  • 6.4 Severe

7 Global Atopic Dermatitis Drugs Market, By Formulation

  • 7.1 Introduction
  • 7.2 Tablets
  • 7.3 Lotions
  • 7.4 Syrups
  • 7.5 Sprays
  • 7.6 Other Formulations

8 Global Atopic Dermatitis Drugs Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Topical Drugs
  • 8.3 Oral Drugs
  • 8.4 Injectable Drugs

9 Global Atopic Dermatitis Drugs Market, By Application

  • 9.1 Introduction
  • 9.2 Phototherapy
  • 9.3 Immunomodulation
  • 9.4 Infection Prevention
  • 9.5 Skin Barrier Dysfunction
  • 9.6 Inflammation
  • 9.7 Itching
  • 9.9 Other Applications

10 Global Atopic Dermatitis Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Sanofi
  • 12.2 Regeneron Pharmaceuticals
  • 12.3 Pfizer Inc.
  • 12.4 Novartis AG
  • 12.5 Eli Lilly and Company
  • 12.6 AbbVie Inc.
  • 12.7 Astellas Pharma Inc.
  • 12.8 LEO Pharma A/S
  • 12.9 Galderma S.A.
  • 12.10 Johnson & Johnson
  • 12.11 Bristol Myers Squibb
  • 12.12 AnaptysBio Inc.
  • 12.13 Encore Dermatology Inc.
  • 12.14 GlaxoSmithKline PLC
  • 12.15 AstraZeneca PLC
  • 12.16 Glenmark Pharmaceuticals

List of Tables

  • Table 1 Global Atopic Dermatitis Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Atopic Dermatitis Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Atopic Dermatitis Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 4 Global Atopic Dermatitis Drugs Market Outlook, By Calcineurin Inhibitors (2021-2030) ($MN)
  • Table 5 Global Atopic Dermatitis Drugs Market Outlook, By Systemic Immunosuppressants (2021-2030) ($MN)
  • Table 6 Global Atopic Dermatitis Drugs Market Outlook, By Phosphodiesterase-4 (PDE4) Inhibitors (2021-2030) ($MN)
  • Table 7 Global Atopic Dermatitis Drugs Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 8 Global Atopic Dermatitis Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 9 Global Atopic Dermatitis Drugs Market Outlook, By Severity (2021-2030) ($MN)
  • Table 10 Global Atopic Dermatitis Drugs Market Outlook, By Mild (2021-2030) ($MN)
  • Table 11 Global Atopic Dermatitis Drugs Market Outlook, By Moderate (2021-2030) ($MN)
  • Table 12 Global Atopic Dermatitis Drugs Market Outlook, By Severe (2021-2030) ($MN)
  • Table 13 Global Atopic Dermatitis Drugs Market Outlook, By Formulation (2021-2030) ($MN)
  • Table 14 Global Atopic Dermatitis Drugs Market Outlook, By Tablets (2021-2030) ($MN)
  • Table 15 Global Atopic Dermatitis Drugs Market Outlook, By Lotions (2021-2030) ($MN)
  • Table 16 Global Atopic Dermatitis Drugs Market Outlook, By Syrups (2021-2030) ($MN)
  • Table 17 Global Atopic Dermatitis Drugs Market Outlook, By Sprays (2021-2030) ($MN)
  • Table 18 Global Atopic Dermatitis Drugs Market Outlook, By Other Formulations (2021-2030) ($MN)
  • Table 19 Global Atopic Dermatitis Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 20 Global Atopic Dermatitis Drugs Market Outlook, By Topical Drugs (2021-2030) ($MN)
  • Table 21 Global Atopic Dermatitis Drugs Market Outlook, By Oral Drugs (2021-2030) ($MN)
  • Table 22 Global Atopic Dermatitis Drugs Market Outlook, By Injectable Drugs (2021-2030) ($MN)
  • Table 23 Global Atopic Dermatitis Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Atopic Dermatitis Drugs Market Outlook, By Phototherapy (2021-2030) ($MN)
  • Table 25 Global Atopic Dermatitis Drugs Market Outlook, By Immunomodulation (2021-2030) ($MN)
  • Table 26 Global Atopic Dermatitis Drugs Market Outlook, By Infection Prevention (2021-2030) ($MN)
  • Table 27 Global Atopic Dermatitis Drugs Market Outlook, By Skin Barrier Dysfunction (2021-2030) ($MN)
  • Table 28 Global Atopic Dermatitis Drugs Market Outlook, By Inflammation (2021-2030) ($MN)
  • Table 29 Global Atopic Dermatitis Drugs Market Outlook, By Itching (2021-2030) ($MN)
  • Table 30 Global Atopic Dermatitis Drugs Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.